- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PCK News
- PM(NOC)
- Procedure
- Prosecution
- Services
- Summary
- Trade Secrets
- Trademark
- Use
- Validity
- Abandonment
- Abstract Theorems
- Abuse of Process
- Accounting of Profits
- Alice/Mayo Test
- Ambiguity
- Anticipation
- Appeal
- Apple
- Artificial Intelligence
- Assignment
- Bargain Theory
- Biosimilar
- Biotech Patents
- Branding
- business
- CAFC
- Canada
- Certificate of Supplementary Protection
- Chemical Patent
- CIPO
- claim
- Claim Construction
- Class Actions
- College of Patent Agents and Trademark Agents
- combination drugs
- Commercial Success
- Common General Knowledge
- Confidential Information
- Confusion
- Contract
- Copyright
- Copyright Infringement
- Costs
- Counterfeit
- Court of Appeals for the Federal Circuit
- COVID-19
- Damages
- Data Protection
- Design Patents
- Distinctiveness
- Diversity
- DNA Patents
- Domain Names
- Dosage Range
- Double Patenting
- Due Care
- E-Commerce
- Enablement
- Estoppel
- Evidence
- Expert Evidence
- Fair Use
- Federal Court
- Federal Court of Appeal
- File Wrapper Estoppel
- Food and Drug Regulations
- Fraud
- funding
- Generic Drugs
- Hague Agreement
- Indefiniteness
- Induced Infringement
- Industrial Designs
- Injunction
- Innovation
- Innovative Drugs
- Insufficient Disclosure
- Intellectual Property
- Inter Partes Review
- Investors
- IP Litigation
- IP Strategy
- IP Treaty
- IPIC
- Jurisdiction
- Law Firm
- Licensing IP
- Madrid Protocol
- Methods of Medical Treatment
- Non-Infringing Alternative
- Non-Practicing Entity
- Novelty
- Obviousness
- Official Marks
- On-Sale Bar
- Overbreadth
- Ownership & Inventorship
- Passing Off
- Patent Act
- Patent Agent
- Patent Appeal Board
- Patent Application
- Patent Drafting
- Patent Fees
- Patent Infringement
- Patent Law
- Patent Lawyer
- Patent Litigation
- Patent Prosecution
- Patent Rules
- Patent Strategy
- Patent Term Adjustment
- Patent Textbook
- Patent Trolls
- Patent Validity
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PM(NOC)
- PMPRB
- Prior Art
- Prior Disclosure
- prior use
- Priority
- Privilege
- Product Specificity
- Promise Doctrine
- Provisional Patent
- Punitive Damages
- Reinstatement
- Remedies
- SCOTUS
- Selection Patent
- Software
- Software Copyright
- Software Patent
- Sound Prediction
- Springboard Profits
- SRED
- Standard of Review
- Start-up
- Startups
- Supreme Court of Canada
- Technology
- Trade Secrets
- Trademark
- Trademark Agent
- Trademark Expungement
- Trademark Infringement
- Trademark Law
- Trademark Opposition
- Trademark Registration
- Trademarks Act
- United States
- Use
- USPTO
- Utility
December 23, 2013
December 23, 2013
Re. Patent Application 2,223,198 CD 1344 Background Patent application 2,223,198 is for a nutritional composition that has successfully caused Chrohn’s disease to go into […]
December 23, 2013
December 23, 2013
Re. Application 2,365,923 CD 1343 Background The Application is for a patent for the use of a drug to treat patients suffering from a rare genetic […]
December 23, 2013
December 23, 2013
Re: Patent Application 2,237,960 CD 1342 Background The application relates to the manufacture of precipitated calcium carbonate from impure calcium oxide. On 17th of […]
December 23, 2013
December 23, 2013
Apotex Inc. v Takeda Canada Inc. 2013 FC 1237 Background This is an application under section 8 of the PM(NOC) process dealing with lost revenue […]
November 28, 2013
November 28, 2013
Apotex Inc. v. H. Lundbeck A/S [2013 FC 1188] Background Apotex was the losing party in an impeachment trial of Lundbeck’s Canadian Patent 1,339,452 in which Lundbeck […]
November 26, 2013
November 26, 2013
Bell Helicopter Textron Canada Limitee v Eurocopter, 2013 FCA 261 Background The Federal Court of Appeal declined a motion under Rule 397 of the Federal Court […]
November 7, 2013
November 7, 2013
SEC Filing Background Twitter’s SEC filing for their initial public offering (IPO) were recently released. Within the filing there are several interesting issues related to their […]
October 31, 2013
October 31, 2013
Background The Federal Government has recently tabled Bill C-8 entitled An Act to amend the Copyright Act and the Trade-marks Act and to make consequential amendments […]
October 29, 2013
October 29, 2013
Teva Canada Limited v Pfizer Canada Inc. [2013 FC 1066] Background The present action is pursuant to s. 8 of the PM(NOC) Regulations for damages […]
October 29, 2013
October 29, 2013
Bayer Inc. v Cobalt Pharmaceuticals Company [2013 FC 1061] Background This proceeding is an application under the NOC regulations by Bayer seeking a prohibition order to […]
October 24, 2013
October 24, 2013
Summary Canada and the EU have signed a Comprehensive Economic and Trade Agreement (CETA). The agreement includes potential changes to the Canadian pharmaceutical industry. The most […]
October 24, 2013
October 24, 2013
Summary A new bill (H.R. 3309) was introduced entitled The Innovation Act of 2013. The bill is cosponsored by Howard Coble (R-N.C.) the chairman of the […]
October 24, 2013
October 24, 2013
Mylan Pharmaceuticals ULC v Bristol-Myers Squibb Canada Co. [2013 FCA 231] Background This is an appeal of a cost award from a Judgment of Justice Barnes […]
October 22, 2013
October 22, 2013
Pfizer Canada Inc. v Apotex Inc., [2013 FC 1036] Background This is a decision of Prothonotary Aalto dealing with the consequence of a reversal order. […]
October 18, 2013
October 18, 2013
Teva Canada Limited v Novartis Pharmaceuticals Canada Inc, 2013 FCA 244. Background Teva appealed a judgment of Justice Hughes(2012 FC 283) where a prohibition order was […]
October 18, 2013
October 18, 2013
F Hoffmann-La Roche AG v Commissioner of Patents, 2013 FC 1001. Background This is an application for an order pursuant to s. 20 of the […]
October 18, 2013
October 18, 2013
Distrimedic Inc v Dispill Inc. 2013 FC 1043 Background The patent at issue is Canadian Patent No. 2,207,045. The product is a kit for the manufacture […]
October 8, 2013
October 8, 2013
Novartis Pharmaceuticals Canada Inc. v Cobalt Pharmaceuticals Company [2013 FC 985] Affirmed on Appeal [2014 FCA 17] Background This is an application under the NOC regulations […]
October 2, 2013
October 2, 2013
Interbrand released its annual Best Global Brands ranking for 2013 on September 30, 2013. The report, whose methodology is described here, proves once again that brands […]
October 2, 2013
October 2, 2013
Re. Patent Application No. 2,144,068, CD 1339 This decision was a review by the Patent Appeal Board of the Examiner’s final rejection in respect of Canadian […]